Skip to content

Tarsus Pharmaceuticals, Inc. TARS Number of Exercisable Options

Number of Exercisable Options at other companies

Warby Parker logo
Warby ParkerWRBY
1.6M-2.0%

Other financials

Income statement

See full
Revenue$162.1M+107%
Gross profit$152.7M+109%
Operating income-$6.1M+76.7%
Net income-$7.0M+72.3%
EPS (diluted)-$0.16+75.0%

Balance sheet

See full
Cash & equivalents$104.2M-41.6%
Total debt$88.7M+22.5%
Total equity$349.0M+1.9%
Total assets$581.1M+16.1%

Cash flow

See full
Operating cash flow-$24.7M-19.4%
CapEx$5.8M+886%
Free cash flow-$30.5M-43.4%

Valuation

See full
Market cap$2.85B+41.1%
Enterprise value$2.83B+47.8%
P/S5.3×-3.3×

Profitability

See full
Gross margin42.7%
Operating margin-9.5%-4.2pp
Net margin-9%-4.0pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-14%-5.2pp
Debt / equity0.3×0.0×
Current ratio3.7×-1.8×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s number of exercisable options.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s number of exercisable options?
Tarsus Pharmaceuticals, Inc. (TARS) reported number of exercisable options of 4.1M in Q1 2026.
How has Tarsus Pharmaceuticals, Inc.'s number of exercisable options changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s number of exercisable options increased by 14.6% year-over-year, from 3.6M to 4.1M.
What does number of exercisable options mean?
The number of share-based payment options that have met all vesting requirements and are currently eligible for exercise by the holders. This represents the portion of the equity incentive pool that could be converted into common stock immediately. It is a critical component for calculating fully diluted share counts.